2009
March
Monday, Mar 09, 2009
Genentech, Inc. announced today that the U.S. Food and Drug Administration's (FDA) Oncologic Drugs Advisory Committee (ODAC) will discuss the company's supplemental Biologics License Application (sBLA) for Avastin® (bevacizumab) for people with previously treated glioblastoma during an advisory committee meeting on March 31, 2009.
2007
December
Thursday, Dec 20, 2007
Genentech, in collaboration with the American Academy of Ophthalmology (AAO) and the American Society of Retina Specialists (ASRS), is pleased to provide an update on our joint efforts to address physician questions about access to Avastin® (bevacizumab) after Genentech's January 1, 2008 change to the distribution of the product.
October
Monday, Oct 29, 2007
Genentech recently informed the retinal community that our company would no longer allow compounding pharmacies to purchase Avastin® (bevacizumab), a Genentech-manufactured drug, from authorized wholesale distributors.
Thursday, Oct 11, 2007
Dear Retinal Community Member: On behalf of Genentech, manufacturer of Avastin® (bevacizumab), I am writing to inform you of a change to the distribution of this product.